RCUS vs RCKTW: Which is Better to Buy in 2026?

Side-by-side fundamental comparison based on AI analysis of SEC filings

AI Verdict

RCUS has stronger fundamentals based on our AI analysis.

RCUS
Arcus Biosciences, Inc.
SELL
78%
Confidence
VS
RCKTW
ROCKET PHARMACEUTICALS, INC.
STRONG SELL
85%
Confidence

RCUS vs RCKTW Fundamental Comparison

Metric RCUS RCKTW
Revenue $247.0M $0.0
Net Income $-353.0M $-223.1M
Net Margin -142.9% N/A
ROE -55.9% -80.5%
ROA -31.0% -67.5%
Current Ratio 4.36x 6.38x
Debt/Equity 0.16x 0.00x
EPS $-3.29 $-2.01

Green = Better metric | Red = Weaker metric

View Full RCUS Analysis →
View Full RCKTW Analysis →
Browse Sectors: Technology Healthcare Finance Energy Consumer Industrial
Stock Lists: Strong Buy Undervalued Growth Dividend

You Might Also Compare

RCUS vs AAPL RCKTW vs MSFT RCUS vs GOOGL RCKTW vs AMZN

RCUS vs RCKTW: Frequently Asked Questions

Is RCUS or RCKTW a better buy in 2026?

Based on dual AI fundamental analysis (Claude and ChatGPT), RCUS has stronger fundamentals. RCUS is rated SELL (78% confidence) while RCKTW is rated STRONG SELL (85% confidence). This is not investment advice.

How does RCUS compare to RCKTW fundamentally?

Arcus Biosciences, Inc. has ROE of -55.9% vs ROCKET PHARMACEUTICALS, INC.'s -80.5%. Net margins are -142.9% vs N/A respectively.

Which stock pays higher dividends, RCUS or RCKTW?

RCUS has a dividend yield of N/A or no dividend while RCKTW has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.

Should I invest in RCUS or RCKTW for long term?

For long-term investing, consider that RCUS has SELL rating with 78% confidence, while RCKTW has STRONG SELL rating with 85% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.

What do the AI models say about RCUS vs RCKTW?

Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For RCUS vs RCKTW, the AI consensus favors RCUS based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.